Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 160

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 160
---
, subject to various conditions and may reject all or part of any order. The Underwriter has advised us that they propose initially to offer the shares of common stock to the public at the public
offering price set forth on the cover page of this prospectus and to dealers at a price less a concession not in excess of $[*] per share
of common stock, or Pre-Funded Warrant in lieu thereof. After the shares of common stock and Pre-Funded Warrants are released for sale
to the public, the Underwriter may change the offering price, the concession, and other selling terms at various times.

Discounts and Commissions

The following table provides information regarding
the amount of the discounts and commissions to be paid to the Underwriter by us, before expenses. The information assumes either no
exercise or full exercise of the over-allotment option we granted to the Underwriter:

|                                             |     | Per Share or per Pre-Funded Warrant |     | Total |
|:--------------------------------------------|:----|:------------------------------------|:----|:------|
| Public offering price                       |     | $                                   |     | $     |
| Underwriting discounts and commissions (4%) |     | $                                   |     | $     |
| Proceeds, before expenses, to us            |     | $                                   |     | $     |

The Company has agreed to reimburse the
Underwriter for: (i) reasonable fees of the Underwriter’s legal counsel up to $80,000, and (ii) non-accountable expenses
including background checks, road show expenses (travel, accommodations, means and entertainment), memento transaction memorabilia,
and courier and postage expenses in the amount of $45,000. Prior to the effective date of this prospectus, we will have paid the
Underwriter advances of $45,000, including a $25,000 retainer for its legal counsel and a $20,000 retainer for its anticipated
out-of-pocket costs. Such advance payments will be returned to us to the extent such out-of-pocket expenses are not actually
incurred in accordance with FINRA Rule 5110(g)(4)(A).

We estimate that our total expenses of the offering,
excluding the estimated underwriting discounts and commissions and excluding the non-accountable expense allowance, will be approximately
$[*].

Right of First Refusal

We have granted the Underwriter a right of first refusal for a period of three months commencing on the closing of the offering to act as